Company intelligence / Profile preview

SynapDx

Lexington, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

SynapDx developed a blood-based diagnostic test to identify children at risk for autism spectrum disorder earlier than current clinical practice. The test measures differences in RNA expression. As of the last available updates (~2014), the company had completed or was nearing completion of large prospective clinical studies but did not reach commercialization. There are no reports of FDA approval or market launch.

Therapeutic areas: PsychiatryNeurology
Modalities: Diagnostic testGenomic analysis
Industry: Molecular Diagnostics

Partnerships

Broad Institute (collaboration on next-generation sequencing methods)Illumina (partnership to develop diagnostic tools for ASD)

Beyond the preview

Go deeper on SynapDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynapDx.

Explore the full profile